Deals, Partnering

Apothecary Shops Specialty Pharmacies receives distribution rights from Pfizer

Posted on 08 February 2012

Tags: , , ,

The Apothecary Shops Specialty Pharmacies has received distribution rights from pharmaceutical manufacturer Pfizer for its new drug Inlyta (axitinib), and will begin to provide this new drug to patients immediately. 

On January 27, 2012, Inlyta (axitinib) was approved by the Food and Drug Administration for the treatment of advanced renal cell carcinoma (RCC) after failure of one systemic therapy, and throughout its development was recognized as one of Pfizer's most important experimental medicines.

An oral drug, Inlyta inhibits certain receptors that can influence tumor growth and progression of kidney cancer.

A Food and Drug Administration advisory committee panel noted last December that the oral drug was at least as safe and effective as several previously approved treatments for the disease, but with an improved toxicity profile.

At that time, the Food and Drug Administration Oncologic Drugs Advisory Committee voted 13-0 that Inlyta had a favorable benefit-risk profile for patients with allergic or adverse side effects from previously prescribed medications.

Since opening its first location in Arizona in 1996, The Apothecary Shops has focused on specific areas of disease states, including oncology, and has extensive experience in providing medications for patients with cancer-related illnesses and diseases.

To best serve their oncology patients, The Apothecary Shops have a dedicated oncology team that includes clinical pharmacists, Patient Care Coordinators, Financial Assistance and Prior Authorizations Specialists, and Regional Oncology Account Managers.

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif